Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Key facts
- Where
- Beijing, Shenzhen, and Shijiazhuang, ChinaSee the 4 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in China
- Beijing 302 HospitalBeijing, ChinaTaking people
- Beijing YouAn HospitalBeijing, ChinaTaking people
- Shenzhen Third People's HospitalShenzhen, ChinaTaking people
- The Fifth Hospital of ShijiazhuangShijiazhuang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cell Energy Life Sciences Group Co. LTD
- Trial code
- NCT05939167
- Record updated
- 12 August 2025
- Original description
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.Read full original descriptionShow less
A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Inclusion: Confirmed HIV infection, aged 18-65, both genders; CD4+T count less than 500 cells/ul at baseline; No serious AIDS related events. 3. could understand and sign the informed consent form and comply with the requirements of this study; agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study.
Exclusion: received treatment of hormones or other immunosuppressive drugs for a long time; received immunosuppressive drugs or systemic cytotoxic drugs for more than 3 months before recruiting; drug addiction within 6 months, or the urine drug test is positive; have HBV/HCV/HDV/HEV infection, and the virological test is positive; have HIV-2 infection; have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors; The viral load for CMV and EBV is more than 1000 copies/ML; with serious AIDS related or unrelated events; have poor compliance during treatment; participate in other clinical trials currently; pregnant, breastfeeding, or have fertility requirements; unable or unwilling to provide informed consents, or unable to comply with research requirements; Other serious situations that may hinder clinical trials.